首页
400-620-6333
teprotumumab
功能和特点
有货
切换导航
搜索
基本信息
| 产品名称 | teprotumumab |
|---|
产品属性
| CAS编号和信息 | Ab175673 |
|---|
数据库链接
| IMGT/mAb-DB | 336 |
|---|
关联配体
| Ligand ID | 10612 |
|---|---|
| 名称 | teprotumumab |
| 别名 | RG-1507 |
| 类别 | Antibody |
| 学名 | 4-amino-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide |
| 生物活性评价 |
The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in |
| 评价 |
Teprotumumab is a fully human anti-insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody (antagonist) |
| 单字母多肽序列 | |
| 三字母多肽序列 | |
| 翻译后修饰 | |
| 化学修饰 |
产品问答
产品问答
参考文献
| 1. Feldon SE, Park DJ, O'Loughlin CW, Nguyen VT, Landskroner-Eiger S, Chang D, Thatcher TH, Phipps RP. (2005) Autologous T-lymphocytes stimulate proliferation of orbital fibroblasts derived from patients with Graves' ophthalmopathy.. Invest Ophthalmol Vis Sci, 46 (11): (3913-21). [PMID:16249464] |
| 2. Kurzrock R, Patnaik A, Aisner J, Warren T, Leong S, Benjamin R, Eckhardt SG, Eid JE, Greig G, Habben K et al.. (2010) A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors.. Clin Cancer Res, 16 (8): (2458-65). [PMID:20371689] |
| 3. Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. (2011) R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis.. PLoS ONE, 6 (10): (e26060). [PMID:22022506] |
| 4. Ramalingam SS, Spigel DR, Chen D, Steins MB, Engelman JA, Schneider CP, Novello S, Eberhardt WE, Crino L, Habben K et al.. (2011) Randomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.. J Clin Oncol, 29 (34): (4574-80). [PMID:22025157] |
| 5. Mahadevan D, Sutton GR, Arteta-Bulos R, Bowden CJ, Miller PJ, Swart RE, Walker MS, Haluska P, Munster PN, Marshall J et al.. (2014) Phase 1b study of safety, tolerability and efficacy of R1507, a monoclonal antibody to IGF-1R in combination with multiple standard oncology regimens in patients with advanced solid malignancies.. Cancer Chemother Pharmacol, 73 (3): (467-73). [PMID:24390424] |
| 6. Chen H, Mester T, Raychaudhuri N, Kauh CY, Gupta S, Smith TJ, Douglas RS. (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes.. J Clin Endocrinol Metab, 99 (9): (E1635-40). [PMID:24878056] |
| 7. Qu X, Wu Z, Dong W, Zhang T, Wang L, Pang Z, Ma W, Du J. (2017) Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy.. Oncotarget, 8 (17): (29501-29518). [PMID:28427155] |
| 8. Huang Y, Fang S, Li D, Zhou H, Li B, Fan X. (2019) The involvement of T cell pathogenesis in thyroid-associated ophthalmopathy.. Eye (Lond.), 33 (2): (176-182). [PMID:30531993] |
| 9. Douglas RS. (2019) Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis.. Eye (Lond.), 33 (2): (183-190). [PMID:30575804] |
上海阿拉丁生化科技股份有限公司
? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任
危险品化学品经营许可证（带存储）